Fractyl CEO: Revita Has Potential to Transform Weight Maintenance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
"We believe Revita has the potential to offer a transformational new approach to durable weight maintenance and a clinically needed off ramp from GLP-1 therapy. Our first quarter results reflect continued execution across every dimension of our business toward that goal," said Harith Rajagopalan, co-founder and CEO of Fractyl. "Topline 6-month randomized data from the REMAIN-1 Pivotal Cohort remains on track for early Q4 2026. This registrational study is prospectively designed and statistically powered to demonstrate Revita's potential effect across the full cohort, with enrichment in participants with higher run-in weight loss and longer ablation length. Ahead of that readout, we expect to report 1-year REVEAL-1 Cohort data in Q2 2026 and 1-year REMAIN-1 Midpoint Cohort randomized data in Q3 2026. Fractyl stands alone in developing the first potential procedural option for post-GLP-1 weight maintenance, and with cash runway into early 2027, we are funded beyond the anticipated pivotal data readout."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GUTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GUTS
Wall Street analysts forecast GUTS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.841
Low
2.00
Averages
5.00
High
8.00
Current: 0.841
Low
2.00
Averages
5.00
High
8.00
About GUTS
Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fractyl Health (GUTS) Q1 2026 Earnings Call Insights
- Financial Recovery: Fractyl Health reported a net income of $9.2 million for Q1 2026, a significant improvement from a net loss of $43.7 million in Q4 2025, although this shift was primarily driven by a non-cash accounting adjustment, indicating a need for cautious interpretation of operational performance.
- R&D Progress: The REMAIN-1 pivotal cohort has completed randomizations with over 300 participants in the U.S., maintaining a participant retention rate exceeding 90%, and the company is on track to deliver 6-month primary endpoint data in early Q4 2026, which could enhance investor confidence.
- Accelerated Regulatory Pathway: The recently announced RAPID coverage pathway by CMS and FDA is expected to materially derisk and potentially accelerate the commercialization reimbursement timeline for Revita, thereby strengthening the company's competitive position in the market.
- New Drug Candidate Approval: Fractyl Health has received authorization from EU regulatory authorities to initiate the Phase I/II study of the RJVA-001 drug candidate, with preliminary data expected in the second half of 2026, marking a significant milestone in the company's drug development efforts.
See More
Avaí Bio Initiates α-Klotho Cell Production Phase
- Market Growth Potential: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating strong growth momentum that drives strategic positioning for companies like Avaí Bio.
- Regulatory Flexibility Enhancement: The FDA's easing of manufacturing requirements for cell and gene therapies accelerates the approval timeline for life-saving products, creating a historic shift that provides companies with scalable bioproduction infrastructure and enhances market competitiveness.
- Cell Bank Development: Avaí Bio, in partnership with Austrianova, has begun manufacturing a Master Cell Bank (MCB) for α-Klotho protein, establishing a stable production foundation that ensures product quality and consistency for future cell therapies.
- Clinical Trial Outlook: The production of α-Klotho cells will directly support Austrianova's Cell-in-a-Box® platform, aiming to provide patients with durable anti-aging treatments, marking a significant advancement for the company in addressing aging-related diseases.
See More
Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
- Market Growth: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating robust growth potential that drives demand for cell and gene therapies.
- FDA Regulatory Impact: The FDA's easing of manufacturing requirements accelerates the approval timeline for life-saving products, creating sustainable value for therapy developers like Avaí Bio, marking a historic shift in the industry.
- Strategic Production Capacity: As biologics production capacity becomes a coveted strategic asset, Avaí Bio and Austrianova have commenced manufacturing a Master Cell Bank of α-Klotho protein, ensuring high quality and consistency for future production.
- Innovative Technology Application: Avaí Bio's cell therapy products will be developed using the Cell-in-a-Box® encapsulation platform, aiming to provide durable anti-aging treatments for patients, signifying the company's successful pivot into biotechnology.
See More
Fractyl Health Q4 2025 Earnings Report Analysis
- Financial Overview: Fractyl Health Inc reported a net loss of $43.7 million for Q4 2025, significantly up from $25 million in Q4 2024, indicating pressure on cost control that may impact future funding capabilities.
- R&D and Operating Expenses: Research and development expenses were $16.5 million, down from $20.3 million in Q4 2024, reflecting a cautious approach to R&D investment, while SG&A expenses rose to $6.8 million, increasing operational burdens.
- Cash Flow and Funding Outlook: As of December 31, 2025, the company had approximately $81.5 million in cash and cash equivalents, expected to fund operations into early 2027, providing some financial flexibility despite economic pressures.
- FDA Feedback and Market Opportunity: Fractyl Health received favorable feedback from the FDA regarding the Revita device, indicating potential Class II device classification, which, combined with a growing market demand, could provide strong support for the company's future commercialization efforts.
See More
Fractyl Health Q4 2025 Earnings Call Insights
- Revita Platform Progress: CEO Harith Rajagopalan emphasized the Revita platform's significance for weight maintenance post-GLP-1 discontinuation, with favorable FDA feedback on the filing strategy laying a solid foundation for future growth.
- Clinical Trial Data: The company has enrolled over 300 participants in the REMAIN-1 study, with a retention rate exceeding 95%, demonstrating strong execution in clinical trials and confidence in upcoming data releases.
- Improved Financial Position: CFO Lara Weber reported R&D expenses of $16.5 million for Q4 2025, down from $20.3 million in Q4 2024, indicating progress in cost control measures.
- Future Outlook: Management expects to deliver 6-month primary endpoint data from the REMAIN-1 study in early Q4 2026 and plans to submit a De Novo application later that year, reflecting confidence in future growth prospects.
See More
Fractyl Health Reports Increased Q4 Losses Amid Market Challenges
- Increased Net Loss: For the fourth quarter ended December 31, 2025, Fractyl Health reported a net loss of $43.7 million, significantly up from $25.0 million in the same period of 2024, indicating ongoing challenges in the market environment.
- Adjusted EBITDA Improvement: The adjusted EBITDA for Q4 2025 was negative $21.2 million, an improvement from negative $22.1 million in Q4 2024, primarily due to a reduction in operating expenses, showcasing the company's efforts in cost control.
- Strong Cash Position: As of December 31, 2025, Fractyl had approximately $81.5 million in cash and cash equivalents, and with an additional $4.1 million from warrant exercises in January 2026, the company believes it can fund operations into early 2027, enhancing market confidence in its operational sustainability.
- Low Market Expectations: Fractyl Health faces low market expectations regarding its future growth potential; however, analysts suggest that upcoming catalysts in 2026 may present trading opportunities, reflecting a potential reassessment of the company's value by the market.
See More
Fractyl Health (GUTS) Q1 2026 Earnings Call Insights
- Financial Recovery: Fractyl Health reported a net income of $9.2 million for Q1 2026, a significant improvement from a net loss of $43.7 million in Q4 2025, although this shift was primarily driven by a non-cash accounting adjustment, indicating a need for cautious interpretation of operational performance.
- R&D Progress: The REMAIN-1 pivotal cohort has completed randomizations with over 300 participants in the U.S., maintaining a participant retention rate exceeding 90%, and the company is on track to deliver 6-month primary endpoint data in early Q4 2026, which could enhance investor confidence.
- Accelerated Regulatory Pathway: The recently announced RAPID coverage pathway by CMS and FDA is expected to materially derisk and potentially accelerate the commercialization reimbursement timeline for Revita, thereby strengthening the company's competitive position in the market.
- New Drug Candidate Approval: Fractyl Health has received authorization from EU regulatory authorities to initiate the Phase I/II study of the RJVA-001 drug candidate, with preliminary data expected in the second half of 2026, marking a significant milestone in the company's drug development efforts.
See More
Avaí Bio Initiates α-Klotho Cell Production Phase
- Market Growth Potential: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating strong growth momentum that drives strategic positioning for companies like Avaí Bio.
- Regulatory Flexibility Enhancement: The FDA's easing of manufacturing requirements for cell and gene therapies accelerates the approval timeline for life-saving products, creating a historic shift that provides companies with scalable bioproduction infrastructure and enhances market competitiveness.
- Cell Bank Development: Avaí Bio, in partnership with Austrianova, has begun manufacturing a Master Cell Bank (MCB) for α-Klotho protein, establishing a stable production foundation that ensures product quality and consistency for future cell therapies.
- Clinical Trial Outlook: The production of α-Klotho cells will directly support Austrianova's Cell-in-a-Box® platform, aiming to provide patients with durable anti-aging treatments, marking a significant advancement for the company in addressing aging-related diseases.
See More
Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
- Market Growth: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating robust growth potential that drives demand for cell and gene therapies.
- FDA Regulatory Impact: The FDA's easing of manufacturing requirements accelerates the approval timeline for life-saving products, creating sustainable value for therapy developers like Avaí Bio, marking a historic shift in the industry.
- Strategic Production Capacity: As biologics production capacity becomes a coveted strategic asset, Avaí Bio and Austrianova have commenced manufacturing a Master Cell Bank of α-Klotho protein, ensuring high quality and consistency for future production.
- Innovative Technology Application: Avaí Bio's cell therapy products will be developed using the Cell-in-a-Box® encapsulation platform, aiming to provide durable anti-aging treatments for patients, signifying the company's successful pivot into biotechnology.
See More
Fractyl Health Q4 2025 Earnings Report Analysis
- Financial Overview: Fractyl Health Inc reported a net loss of $43.7 million for Q4 2025, significantly up from $25 million in Q4 2024, indicating pressure on cost control that may impact future funding capabilities.
- R&D and Operating Expenses: Research and development expenses were $16.5 million, down from $20.3 million in Q4 2024, reflecting a cautious approach to R&D investment, while SG&A expenses rose to $6.8 million, increasing operational burdens.
- Cash Flow and Funding Outlook: As of December 31, 2025, the company had approximately $81.5 million in cash and cash equivalents, expected to fund operations into early 2027, providing some financial flexibility despite economic pressures.
- FDA Feedback and Market Opportunity: Fractyl Health received favorable feedback from the FDA regarding the Revita device, indicating potential Class II device classification, which, combined with a growing market demand, could provide strong support for the company's future commercialization efforts.
See More
Fractyl Health Q4 2025 Earnings Call Insights
- Revita Platform Progress: CEO Harith Rajagopalan emphasized the Revita platform's significance for weight maintenance post-GLP-1 discontinuation, with favorable FDA feedback on the filing strategy laying a solid foundation for future growth.
- Clinical Trial Data: The company has enrolled over 300 participants in the REMAIN-1 study, with a retention rate exceeding 95%, demonstrating strong execution in clinical trials and confidence in upcoming data releases.
- Improved Financial Position: CFO Lara Weber reported R&D expenses of $16.5 million for Q4 2025, down from $20.3 million in Q4 2024, indicating progress in cost control measures.
- Future Outlook: Management expects to deliver 6-month primary endpoint data from the REMAIN-1 study in early Q4 2026 and plans to submit a De Novo application later that year, reflecting confidence in future growth prospects.
See More
Fractyl Health Reports Increased Q4 Losses Amid Market Challenges
- Increased Net Loss: For the fourth quarter ended December 31, 2025, Fractyl Health reported a net loss of $43.7 million, significantly up from $25.0 million in the same period of 2024, indicating ongoing challenges in the market environment.
- Adjusted EBITDA Improvement: The adjusted EBITDA for Q4 2025 was negative $21.2 million, an improvement from negative $22.1 million in Q4 2024, primarily due to a reduction in operating expenses, showcasing the company's efforts in cost control.
- Strong Cash Position: As of December 31, 2025, Fractyl had approximately $81.5 million in cash and cash equivalents, and with an additional $4.1 million from warrant exercises in January 2026, the company believes it can fund operations into early 2027, enhancing market confidence in its operational sustainability.
- Low Market Expectations: Fractyl Health faces low market expectations regarding its future growth potential; however, analysts suggest that upcoming catalysts in 2026 may present trading opportunities, reflecting a potential reassessment of the company's value by the market.
See More
